Vorinostat

被引：364
作者：
Grant, Steven [1 ]
Easley, Chris
Kirkpatrick, Peter
机构：
[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Richmond, VA 23298 USA
[2] IMS Hlth, London NW1 6JB, England
来源：
NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 01期
关键词：
D O I：
10.1038/nrd2227
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Vorinostat (Zolinza; Merck) was approved by the US FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. It is the first in a new class of anticancer agents that inhibit histone deacetylases, which have a key role in the epigenetic regulation of gene expression.
引用
收藏
页码：21 / 22
页数：2
相关论文
共 12 条
  • [1] Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
    Bali, P
    Pranpat, M
    Bradner, J
    Balasis, M
    Fiskus, W
    Guo, F
    Rocha, K
    Kumaraswamy, S
    Boyapalle, S
    Atadja, P
    Seto, E
    Bhalla, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) : 26729 - 26734
  • [2] Anticancer activities of histone deacetylase inhibitors
    Bolden, Jessica E.
    Peart, Melissa J.
    Johnstone, Ricky W.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) : 769 - 784
  • [3] DUVIC M, 2006, BLOOD 0907
  • [4] Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
    Kelly, WK
    Marks, PA
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (03): : 150 - 157
  • [5] Immunopathogenesis and therapy of cutaneous T cell lymphoma
    Kim, EJ
    Hess, S
    Richardson, SK
    Newton, S
    Showe, LC
    Benoit, BM
    Ubriani, R
    Vittorio, CC
    Junkins-Hopkins, JM
    Wysocka, M
    Rook, AH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) : 798 - 812
  • [6] Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
    Richon, VM
    Sandhoff, TW
    Rifkind, RA
    Marks, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) : 10014 - 10019
  • [7] Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
    Richon, VM
    Webb, Y
    Merger, R
    Sheppard, T
    Jursic, B
    Ngo, L
    Civoli, F
    Breslow, R
    Rifkind, RA
    Marks, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) : 5705 - 5708
  • [8] A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
    Richon, VM
    Emiliani, S
    Verdin, E
    Webb, Y
    Breslow, R
    Rifkind, RA
    Marks, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (06) : 3003 - 3007
  • [9] Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate
    Trachootham, Dunyaporn
    Zhou, Yan
    Zhang, Hui
    Demizu, Yusuke
    Chen, Zhao
    Pelicano, Helene
    Chiao, Paul J.
    Achanta, Geetha
    Arlinghaus, Ralph B.
    Liu, Jinsong
    Huang, Peng
    [J]. CANCER CELL, 2006, 10 (03) : 241 - 252
  • [10] Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
    Ungerstedt, JS
    Sowa, Y
    Xu, WS
    Shao, Y
    Dokmanovic, M
    Perez, G
    Ngo, L
    Holmgren, A
    Jiang, X
    Marks, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) : 673 - 678
12